Excellent in vivo bystander activity of fludarabine phosphate against human glioma xenografts that express the escherichia coli purine nucleoside phosphorylase gene

Cancer Research
Jeong S HongEric J Sorscher

Abstract

Escherichia coli purine nucleoside phosphorylase (PNP) expressed in tumors converts relatively nontoxic prodrugs into membrane-permeant cytotoxic compounds with high bystander activity. In the present study, we examined tumor regressions resulting from treatment with E. coli PNP and fludarabine phosphate (F-araAMP), a clinically approved compound used in the treatment of hematologic malignancies. We tested bystander killing with an adenoviral construct expressing E. coli PNP and then more formally examined thresholds for the bystander effect, using both MuLv and lentiviral vectoring. Because of the importance of understanding the mechanism of bystander action and the limits to this anticancer strategy, we also evaluated in vivo variables related to the expression of E. coli PNP (level of E. coli PNP activity in tumors, ectopic expression in liver, percentage of tumor cells transduced in situ, and accumulation of active metabolites in tumors). Our results indicate that F-araAMP confers excellent in vivo dose-dependent inhibition of bystander tumor cells, including strong responses in subcutaneous human glioma xenografts when 95 to 97.5% of the tumor mass is composed of bystander cells. These findings define levels of E. coli PNP...Continue Reading

References

Jan 1, 1968·Journal of Medicinal Chemistry·J A Montgomery, K Hewson
Jan 1, 1994·Methods in Cell Biology·T C BeckerC B Newgard
Oct 10, 1997·Human Gene Therapy·W B ParkerE J Sorscher
Jun 20, 1998·Biochemical Pharmacology·W B ParkerL L Bennett
Mar 8, 2000·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·L MohrJ R Wands
Aug 30, 2001·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·T U KrohneL Mohr
Feb 27, 2003·The Journal of Pharmacology and Experimental Therapeutics·Vijayakrishna K GadiEric J Sorscher
Jan 1, 2004·Chemistry & Biology·Eric M BennettSteven E Ealick

❮ Previous
Next ❯

Citations

Jun 28, 2011·Cancer Gene Therapy·S BossowG Ungerechts
Feb 23, 2007·Nature Clinical Practice. Endocrinology & Metabolism·Marinella Messina, Bruce G Robinson
Dec 5, 2009·Journal of Experimental & Clinical Cancer Research : CR·Sepideh AfsharSherie L Morrison
Jul 25, 2006·Expert Opinion on Investigational Drugs·Pamela J Russell, Aparajita Khatri
Oct 20, 2015·Journal of Cellular Biochemistry·Giovanna CacciapuotiMarina Porcelli
May 26, 2015·Advanced Drug Delivery Reviews·Zahra KarjooArash Hatefi
Apr 23, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E L RosenthalE J Sorscher
Sep 3, 2005·Cancer Gene Therapy·S E LawlerE A Chiocca
Jan 10, 2020·Cancer Chemotherapy and Pharmacology·William B ParkerEric J Sorscher
Mar 16, 2018·Oncology Letters·Cun-Zhi LinXiao-Yuan Zhang
Oct 27, 2005·Nucleosides, Nucleotides & Nucleic Acids·William B ParkerJohn A Secrist
Dec 23, 2015·Hip International : the Journal of Clinical and Experimental Research on Hip Pathology and Therapy·Nanna H SillesenHenrik Malchau
Aug 28, 2021·Brain Sciences·Alice Giotta Lucifero, Sabino Luzzi

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.